CN Patent

CN118384166A — 用于调节激酶级联的联芳组合物和方法

Assigned to Athenex Inc · Expires 2024-07-26 · 2y expired

What this patent protects

本申请涉及用于调节激酶级联的联芳组合物和方法。本申请涉及联芳化合物，包含所述化合物的药物组合物，以及使用所述化合物治疗细胞增殖性障碍的方法。

USPTO Abstract

本申请涉及用于调节激酶级联的联芳组合物和方法。本申请涉及联芳化合物，包含所述化合物的药物组合物，以及使用所述化合物治疗细胞增殖性障碍的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN118384166A
Jurisdiction
CN
Classification
—
Expires
2024-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Athenex Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.